EP1075252A2 - Mikroemulsion frei von lösungsmittel und co-lösungsmittel und emulsionvorkonzentrat als wirkstoff freisetzungssytemen - Google Patents

Mikroemulsion frei von lösungsmittel und co-lösungsmittel und emulsionvorkonzentrat als wirkstoff freisetzungssytemen

Info

Publication number
EP1075252A2
EP1075252A2 EP99921098A EP99921098A EP1075252A2 EP 1075252 A2 EP1075252 A2 EP 1075252A2 EP 99921098 A EP99921098 A EP 99921098A EP 99921098 A EP99921098 A EP 99921098A EP 1075252 A2 EP1075252 A2 EP 1075252A2
Authority
EP
European Patent Office
Prior art keywords
agent
composition according
microemulsion
oil component
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921098A
Other languages
English (en)
French (fr)
Inventor
Zebunnissa Ramtoola
Nuala Marie Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of EP1075252A2 publication Critical patent/EP1075252A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention relates to pharmaceutical compositions containing a poorly water soluble therapeutic agent.
  • the present invention relates to the administration, particularly oral administration to a human, of self-emulsifying microemulsion and emulsion preconcentrate formulations or microemulsions and emulsions which contain a poorly water soluble therapeutic agent, an oil component and a surfactant system.
  • These preconcentrates, microemulsions and emulsions have the advantage of being substantially free of or containing only minor amounts of a hydrophilic solvent system.
  • Certain oil mixtures of lipophilic drugs such as a cyclosporin, when combined with vegetable oils or other lipidic substances, surface active agents, solvents and other excipients are known to spontaneously produce dispersions of very low mean particle size, such as ⁇ 200 nm, when mixed with an agueous medium.
  • These dispersions are known as microemulsions and the oily mixtures that produce the microemulsions are popularly referred to as microemulsion preconcentrates.
  • the microemulsion preconcentrates are thought to produce similar dispersions of very low particle size with gastric and other physiological fluids.
  • microemulsion preconcentrate formulations are known, including soft gel formulations, for enhancing the solubilization and oral bioavailability of a poorly water soluble drug compound such as cyclosporin A.
  • these formulations include an active agent, an oil component, a surfactant to emulsify the formulation and a hydrophilic solvent system containing solvents/co-surfactants to solubilize the active agent.
  • Typical solvents/co-surfactants include ethanol, polyethylene glycols, propylene carbonate, dimethylisosorbide, Transcutol and/or Glycofurol.
  • Disadvantages of these formulations include stability or precipitation problems caused by migration of volatile hydrophilic solvents or cosolvents (e.g., ethanol can permeate a gelatin shell at normal storage temperatures), stability or precipitation problems caused by hygroscopic solvents or co-surfactants (e.g., propylene glycols, Transcutol, Glycofurol), and toxicity problems caused by addition of certain solvents or co-surfactants (e.g., dimethylisosorbide).
  • volatile hydrophilic solvents or cosolvents e.g., ethanol can permeate a gelatin shell at normal storage temperatures
  • hygroscopic solvents or co-surfactants e.g., propylene glycols, Transcutol, Glycofurol
  • toxicity problems caused by addition of certain solvents or co-surfactants (e.g., dimethylisosorbide).
  • US 5,603,951 describes a microemulsion concentrate containing cyclosporin as an active ingredient, dimethylisosorbide as a required co-surfactant, a surfactant, and an oil which can be refined fish oil, these components being present in the ratio of 1 :1-5:2-10:1-5.
  • the inventors of the '951 patent added dimethylisosorbide, which is a solvent available under the Tradename ARLASOVE®, to the formulation to address the disadvantages listed above for prior solvents/co-surfactants such as ethanol, Transcutol, or Glycofurol.
  • the '951 preconcentrates are formed by dissolving the cyclosporin in the dimethylisosorbide while heating at approximately 60°C followed by addition of the oil component and the surfactant.
  • WO 97/33610 discloses a microemulsion preconcentrate system containing as co- surfactants propylene carbonate or a mixture of propylene carbonate with polyoxyethylene-polyoxypropylene block copolymers.
  • US 5,589,455 discloses a microemulsion preconcentrate system containing the solvent polyethylene glycol.
  • WO 93/20833 discloses a microemulsion preconcentrate system containing a hydrophilic phase, e.g., Transcutol, Glycofurol, 1 ,2- propylene glycol or ethanol.
  • EP 760237 discloses a microemulsion preconcentrate that includes a phospholipid, preferably lecithin. Phospholipids are disadvantageous in that they are known to have stability issues.
  • the oil component of a conventional microemulsion consists of fatty acid mono-, di- or thglycerides from a vegetable oil; medium chain thglycerides and/or mono- or di-glycerides; mixtures of glycerides and polyglycolized glycerides; tocol, tocopherols, and/or tocotrienols; or hydrophobic alcohols.
  • WO 97/22358 discloses a microemulsions system containing tocol, tocopherols, tocotrienols and derivatives along with propylene carbonate or polyethylene glycols.
  • EP 570715 discloses a microemulsion preconcentrate system containing as a lipophilic phase a mixture of polyglycolized glycerides having a HLB of less than 16.
  • WO 94/25068 discloses a microemulsion preconcentrate system in which hydrophobic alcohols are used in place of the combination of hydrophilic and hydrophobic solvents; while these systems eliminate the need for a hydrophilic solvent system, the hydrophobic alcohols have the disadvantage of tasting bad.
  • Cyclosporins are an example of a class of drugs that is poorly water soluble.
  • Cyclosporin A is a lipophilic cyclic undecapeptide that can be isolated from the fungus Tolypoclodium inflatum Gams and which produces calcium dependent, specific and reversible inhibition of transcription of interleukin-2 and several other cytokines, most notably in T helper lymphocytes. Because of its immunosuppressive properties, it is widely used as first line therapy in the prophylaxis and treatment of transplant rejection (e.g., allo- or xeno-transplant rejection such as in patients receiving heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or comeal transplants) and various autoimmune and inflammatory diseases.
  • transplant rejection e.g., allo- or xeno-transplant rejection such as in patients receiving heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or comeal transplants
  • various autoimmune and inflammatory diseases e.g., allo-
  • CyA is used in the treatment of multi-drug resistance syndrome, for example in patients undergoing chemotherapy or following organ transplantations. In patients with severe disease refractory to standard treatment; CyA is an effective therapy in acute ocular Behcet's syndrome; endogenous uveitis; psoriasis; atopic dermatitis; arthritis, particularly rheumatoid arthritis; active Crohn's disease and nephrotic syndrome.
  • arthritis chronica progrediente and arthritis deformans autoimmune hematological disorders including hemolytic anemia, aplastic anemia, pure red-cell anemia and idiopathic thrombocytopenia, systemic lupus erythematosus, polychondroitis, scleroderma, Wegener granulamtosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-John syndrome, idiopathic sprue, autoimmune inflammatory bowel disease, e.g., ulcerative colitis, endocrine ophthalmology, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes, keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis, juvenile dermatitis, asthma, tumors, hyper
  • CyA has also been used to treat patients with moderate or severe aplastic anemia who are ineligible for bone marrow transplantation and those with primary biliary cirrhosis. CyA may be effective in patients with intractable pyoderma gangrenosum, polymyositis/dermatomyositis or severe, corticosteroid-dependent asthma. CyA is known to have a very specific effect on T-cell proliferation although the precise mechanism remains unclear. A number of non-immunosuppressive analogues of cyclosporin A have been shown to have resistance modifier activity and some are more potent than the parent compound.
  • Nephrotoxicity, hepatotoxicity, hypertension, headache, hypert chosis, gingival hyperplasia, neurological and gastrointestinal effects, thrombocytopenia and microangiopathic hemolytic anemia, hyperkalemia and hyperuricemia and development of skin and lymphoproliferative malignancies are the most common adverse events in cyclosporin recipients.
  • Cyclosporins are highly lipophilic, poorly water soluble and, therefore, have been supplied as an olive oil or peanut oil solution for clinical use.
  • the bioavailability of cyclosporin from such oily solutions is very low and gives rise to great intersubject variation with reported systemic availability ranging from 4 to 25% (Takada, K. et al, J. Pharmacobio-Dyn., 11:80-7 (1988)).
  • the bioavailability of cyclosporin has been reported to be dependent on food, bile and other interacting factors (din. Pharmacokinetics, 24:472-95 (1993)).
  • CyA SAND IMMUNE® for oral administration
  • SAND IMMUNE® is a solution of cyclosporin A in vegetable oil derivatives containing some other inactive excipients.
  • Very high inter- and intra-patient and food dependent variability in the bioavailability of CyA has been observed from this formulation.
  • the commercial microemulsion preconcentrate formulation, NEORAL® has been claimed to provide high bioavailability for CyA with low inter-and intra-patient variability.
  • risks of adverse drug reactions have been indicated on switching to Neoral® (see, e.g., Drug Saf, 16:366-73 (1996); Lancet, 348:205 (1996)).
  • CyA and fish oils have been administered concurrently to organ transplant patients in various clinical trials. For instance, Andreassen et al. (JAAC, 29(6): 1324-31 (1997) reported effective hypertension prophylaxis in heart transplant patients who were given cyclosporin A and 4g of fish oil. Cyclosporin A-treated and fish oil fed renal transplant recipients had improved renal function following a rejection episode (Transplantation,, 54:257 (1992)). US 5,118,493 describes the administration of CyA together with an omega-3 fatty acid oil to mediate the nephrotoxic effects of the cyclosporin.
  • Omega-3 fatty acid oils possess properties that can be used for numerous therapeutic advantages, including treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; immunosuppressive treatment; hypertension prophylaxis in normal humans and in heart transplant patients; coronary heart disease; hyperlipidemia; hypertriglyceridemia; improvement of renal function and nephrotoxicity reduction.
  • autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis
  • immunosuppressive treatment hypertension prophylaxis in normal humans and in heart transplant patients
  • coronary heart disease hyperlipidemia
  • hypertriglyceridemia improvement of renal function and nephrotoxicity reduction.
  • omega-3 polyunsaturated fatty acids compete with omega-6 polyunsaturated fatty acids as a substrate in the arachidonic acid cascade and can therefore alter the synthesis of prostaglandin and leukotrienes, both of which are powerful mediators of inflammation and immune response.
  • omega-3 fatty acid oils are described in US 5,034,415 (diabetes mellitus), US 4,843,095 (rheumatoid arthritis), JP 2253629 (anticancer), US 4,879,312 (enhancing angiogenesis), JP 1290625 (improvement of cerebral function), EP 378,824 (anti-cachexia, cholesterol and triglyceride levels reduction, platelet aggregation inhibition, colon adenocarcinomas growth inhibition), US 5,457,130 (cancer cachexia, malignant tumors, abnormal cAMP levels in adipose tissue, lipolytic activity inhibition) and US 5,436,269 (hepatitis).
  • a further object is to provide self- emulsifying preconcentrates or corresponding microemulsions and emulsions having increased therapeutic agent dosing reproducibility compared to conventional formulations.
  • An additional object is to provide self-emulsifying preconcentrates or corresponding microemulsions or emulsions containing a poorly water soluble therapeutic agent which provide for an enhanced amount of the therapeutic agent in a single dosage unit.
  • An additional object of this invention is to provide stable self- emulsifying preconcentrates, microemulsions or emulsions containing a poorly water soluble therapeutic agent which are substantially free or contain only minor amounts of a hydrophilic solvent system. In this manner, the disadvantages of prior art systems containing hydrophilic solvent systems, such as stability problems, therapeutic agent precipitation problems and/or toxicity problems, are avoided.
  • a further object of this invention is to provide a stable self-emulsifying preconcentrate and/or a microemulsion or emulsion in which the poorly water soluble therapeutic agent is substantially soluble in the oil component, thus eliminating or drastically reducing the need for substantial amounts of a hydrophilic solvent system.
  • An additional object of this invention is to provide a stable self- emulsifying preconcentrate and/or a microemulsion or emulsion containing a poorly water soluble therapeutic agent and a low HLB oil component that is free or substantially free of a hydrophilic solvent system.
  • a further object of this invention is to provide a stable self-emulsifying microemulsion or emulsion preconcentrate formulation and/or a microemulsion or emulsion containing a poorly water soluble therapeutic agent which is suitable for formulation into soft or hard capsules for oral administration.
  • a still further object of this invention is to provide a stable self- emulsifying microemulsion or emulsion preconcentrate soft or hard capsule formulation containing an oil component and a poorly water soluble therapeutic agent having relatively high amounts of both the oil component and the poorly water soluble therapeutic agent.
  • stable, self-emulsifying microemulsion or emulsion preconcentrates comprising a poorly water soluble drug can be formed from a two-component self-emulsifying system containing an oil component having an HLB ⁇ 4 and a surfactant system containing one or more surfactants, each surfactant having an HLB from about 10 to 20.
  • This two-component system eliminates or drastically reduces the need for substantial amounts of a hydrophilic solvent system, allowing for formulation of preconcentrates that are substantially free of a hydrophilic solvent system or contain only minor amounts of a hydrophilic solvent system.
  • the self-emulsifying microemulsion and emulsion preconcentrates according to the present invention take the form of a poorly water soluble therapeutic agent substantially solubilized in a low HLB oil component that is capable of being self-emulsified by the surfactant system when the preconcentrate is diluted with an aqueous medium.
  • the present invention provides a self-emulsifying preconcentrate pharmaceutical composition suitable for administration to a mammal, particularly oral administration to a human, and capable of forming an oil-in- water microemulsion or emulsion upon dilution with an aqueous solution, comprising
  • a pharmaceutically effective amount of a low HLB oil component (b) a pharmaceutically effective amount of a low HLB oil component; and (c) a surfactant system consisting essentially of at least one surfactant having an HLB of from about 10 to 20, preferably 13-19, most preferably 15-18; wherein the composition contains minor amounts or is substantially free of a hydrophilic solvent system.
  • the present invention also provides microemulsions or emulsions formed by diluting a self-emulsifying preconcentrate with an aqueous solution.
  • compositions according to this invention are substantially free or contain only minor amounts of a hydrophilic solvent system, the disadvantages of the prior art systems given above are avoided.
  • Preferred therapeutic agents include a cyclosporin, particularly cyclosporin A, nifedipine or indomethacin and other Class 4 drugs.
  • Preferred low HLB oil components include Labrafil M1944CS; Labrafil M2125CS; and fish oil or other omega-3 fatty acid oils.
  • Preferred omega-3 fatty acid oils include omega-3 free fatty acids, omega-3 fatty acid thglycerides and omega- 3 fatty acid ethyl esters, such as EPA, DHA, thglycerides of EPA, thglycerides of DHA, ethyl esters of EPA, ethyl esters of DHA and mixtures thereof.
  • fish oil When fish oil is employed in the compositions of the present invention, it is preferable to use fish oil containing at least 50%, preferably at least 70%, more preferably at least 80% omega-3 fatty acid oil to obtain a pharmaceutically effective amount of an omega-3 fatty acid oil in a minimal volume
  • Figure 1 shows a ternary phase diagram for the placebo system described in Example 3 upon a 1 to 20 dilution of the preconcentrate with water.
  • the diagram plots the relative concentration of Labrasol (0 to 100%), the concentration of the oil component Labrafil M1944CS (0 to 100%), and the concentration of Cremophor RH40 (0 to 100%) for the placebo system.
  • the relative concentration of Labrasol increases from 0% at the lower right hand margin of the diagram to 100% at the lower left corner; the relative concentration of Cremophor RH40 increases from 0% at the baseline of the diagram to 100% at the apex; and the relative concentration of Labrafil M1944CS increases from 0% at the apex to 100% at the lower right hand corner of the diagram.
  • the shaded area identifies those compositions having C1 , C1/C2 or C2 clarity as the microemulsion region for a 1 to 20 dilution of the preconcentrate with water;
  • Figure 2 shows a ternary phase diagram for the 100 mg CyA system described in Example 3 upon a 1 to 20 dilution of the preconcentrate with water. The diagram plots the relative concentration of Labrasol (0 to 100%), the concentration of Labrafil M1944CS (0 to 100%), and the concentration of Cremophor RH40 (0 to 100%) for compositions containing 100 mg CyA.
  • the relative concentration of Labrasol increases from 0% at the lower right hand margin of the diagram to 100% at the lower left corner; the relative concentration of Cremophor RH40 increases from 0% at the baseline of the diagram to 100% at the apex; and the relative concentration of Labrafil M1944CS increases from 0% at the apex to 100% at the lower right hand corner of the diagram.
  • the shaded area identifies those compositions having C1 , C1/C2 or C2 clarity as the microemulsion region for a 1 to 20 dilution of the preconcentrate with water;
  • Figure 3 shows a pseudo-ternary phase diagram for the placebo system described in Example 13 upon a 1 to 20 dilution of the preconcentrate with water.
  • the diagram plots the relative concentration of Labrasol (0 to 100%), the concentration of the omega-3 fatty acid oil K85TG (0 to 100%), and the concentration of Cremophor RH40:Tween 80 in a 2:1 ratio (0 to 100%) for the placebo system.
  • the relative concentration of Labrasol increases from 0% at the lower right hand margin of the diagram to 100% at the lower left corner; the relative concentration of Cremophor RH40:Tween 80 in a 2:1 ratio increases from 0% at the baseline of the diagram to 100% at the apex; and the relative concentration of K85TG increases from 0% at the apex to 100% at the lower right hand corner of the diagram.
  • the shaded area identifies those compositions having C1 , C1/C2 or C2 clarity as the microemulsion region for a 1 to 20 dilution of the preconcentrate with water; and
  • Figure 4 shows a pseudo-ternary phase diagram for the 100 mg CyA system described in Example 13 upon a 1 to 20 dilution of the preconcentrate with water.
  • the diagram plots the relative concentration of Labrasol (0 to 100%), the concentration of the omega-3 fatty acid oil K85TG (0 to 100%), and the concentration of Cremophor RH40:Tween 80 in a 2:1 ratio (0 to 100%) for compositions containing 100 mg CyA.
  • the relative concentration of Labrasol increases from 0% at the lower right hand margin of the diagram to 100% at the lower left corner; the relative concentration of Cremophor RH40:Tween 80 in a 2:1 ratio increases from 0% at the baseline of the diagram to 100% at the apex; and the relative concentration of K85TG increases from 0% at the apex to 100% at the lower right hand corner of the diagram.
  • the shaded area identifies those compositions having C1 , C1/C2 or C2 clarity as the microemulsion region for a 1 to 20 dilution of the preconcentrate with water.
  • low HLB oil component means a natural or synthetic pharmaceutically acceptable oil or mixture of oils in which the oil or mixture of oils has a hydrophile-lipophile balance (HLB) of ⁇ 4.
  • Example low HLB oil components include, but are not limited to, medium and long chain (e.g., >C13) fatty acids and their mono/di/thglycerides or esters having a HLB ⁇ 4; unsaturated fatty acids and their mono/di/triglycerides or esters having a HLB ⁇ 4; and natural oils such as canoia, soybean, corn, olive, sunflower and their mono/di/triglycerides or esters having a HLB ⁇ 4; or mixtures thereof.
  • medium and long chain e.g., >C13
  • unsaturated fatty acids and their mono/di/triglycerides or esters having a HLB ⁇ 4 unsaturated fatty acids and their mono/di/triglycerides or esters having a HLB ⁇ 4
  • natural oils
  • Preferred low HLB oil components include esters, particularly the ethyl esters, of medium and long chain fatty acids.
  • Specific examples of low HLB oil components include, but are not limited to, Labrafil M1944CS; Labrafil M2125CS; ethyl oleate and oleic acid; omega-6 fatty acids and their mono/di/triglycerides or esters such as ethyl esters; and fish oil and other omega-3 fatty acid oils as defined below and mixtures thereof.
  • oils that are not low HLB oil components include Miglyol 812 (HLB-8-10); Gelucire 44/14 (HLB-14); Gelucire 48/09 (HLB-9); and Labrafil WO 2609 BS (HLB-6).
  • omega-3 fatty acid oil means a natural or synthetic omega-3 fatty acid, and pharmaceutically acceptable esters, derivatives, precursors or salts thereof and mixtures thereof.
  • omega-3 fatty acid oils include but are not limited to omega-3 polyunsaturated, long-chain fatty acids such as a eicosapenta-5, 8,11 ,14,17- enoic acid (hereinafter "EPA"), docosahexa-4,7, 10,13,16,19-enoic acid (hereinafter "DHA”), and ⁇ -linolenic acid; esters of an omega-3 fatty acid with glycerol such as mono-, di- and thglycerides; esters of the omega-3 fatty acid and a primary alcohol such as fatty acid methyl esters and fatty acid ethyl esters; precursors of an omega-3 fatty acid oil, such as EPA and DHA precursor ⁇ -linolenic acid; and derivatives such as poly
  • Preferred omega-3 fatty acid oils are EPA or DHA, thglycerides thereof, ethyl esters thereof and mixtures thereof.
  • the omega-3 fatty acids or their esters, derivatives, precursors, salts and mixtures thereof can be used either in their pure form or as a component of an oil such as fish oil (otherwise known as marine oil), preferably highly purified fish oil concentrates, or perilla oil or marine microalgae oil.
  • Suitable fish oils are, for example, those types which are recovered in substantial quantities from cold- water fish, such as pilchard oil, menhaden oil, Peruvian fish oil, sardine oil, salmon oil, herring oil, and mackerel oil.
  • the fish oil has a high omega-3 fatty acid oil content, such as 50% or higher, more preferably, 70% or higher, most preferably 80% or higher.
  • suitable omega-3 fatty acid oils include the following oils available from Croda Oleochemicals (England): Incromega TG3525 (35:25 EPA:DHA ratio; thglycerides), Incromega E5015 (50:15 EPA: DHA ratio; ethyl esters) and the following oils available from Pronova Biocare (Sandefjord, Norway): EPAX6000FA, EPAX5000TG, EPAX4510TG, EPAX2050TG, K85TG, K85EE, K80EE and EPAX7010EE (further details listed in Table 1 herein).
  • Preferred mixtures include mixtures of fatty acid ethyl esters and fatty acids; fatty acid ethyl esters and fatty acid thglycerides; fatty acids and fatty acid thglycerides; and fatty acid esters, fatty acid triglycerides and fatty acids such as mixtures containing K85EE and EPAX6000FA; EPAX5000TG and EPAX6000FA; K85EE and EPAX5000TG; and K85EE, EPAX6000FA and EPAX5000TG.
  • the term "therapeutic agent” means a poorly water soluble drug having therapeutic use in a mammal, especially a human, or a combination of such poorly water soluble drugs wherein the drug or combination of drugs is insoluble in water or has an aqueous solubility of less than about 1 part per 1000 parts of water by weight at 20°C.
  • the therapeutic agent can be selected from a variety of known types of drugs including, but not limited to, analgesics, anti-allergic agents, anti- fungals, anti-inflammatory agents, anti-arrythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, anti-epilepsy agents, antihypertensive agents, anti-gout agents, anti-malarials, anti-migraine agents, antimuscarinic agents, antineoplastic agents, anti-protozoal agents, anxiolytics, thyroids, anti-thyroids, antivirals, anoretics, bisphosphonates, cardiac inotropic agents, cardiovascular agents, corticosteroids, diuretics, dopaminergic agents, gastrointestinal agents, hemostatics, histamine receptor antagonists, hypnotics, immunosuppressants, kidney protective agents, lipid regulating agents, muscle relaxants, neuroleptics, neurotropic agents, opioid agonists and antagonists, parasympathomimetics, proteas
  • the therapeutic agent may comprise a combination of poorly water-soluble drugs.
  • therapeutic agents include nephrotoxic drugs such as cyclosporins and amphotehcin B; indomethacin; nifedipine; cardiotoxic drugs such as amphotehcin B and FK506; drugs with immunosuppressive effects or anti-inflammatory drugs such as drugs for treating rheumatology, arthritis, psoriasis, inflammatory bowel disease, Crohn's disease or demyelinating diseases including multiple sclerosis; anti-tumor drugs such as melphalan, chlormethine, extramustinephosphate, uramustine, ifosfamide, mannomustine, trifosfamide, streptozotocin, mitobronitol, methotrexate, fluorouracil, cytarabine, tegafur, idoxide, taxol, paclitaxel, daunomycin, daunorubicin, bleomycin, amphot
  • compositions according to this invention may also advantageously provide for an additive or synergistic therapeutic effect between the therapeutic agent and the omega-3 fatty acid oil or mediation of at least one negative side effect of the therapeutic agent by the omega-3 fatty acid oil.
  • omega-3 fatty acid oil reduces the nephrotoxicity of cyclosporin when co-administered, allowing treatment with higher levels of cyclosporin and producing a greater clinical response at a given dose of cyclosporin.
  • a pharmaceutically effective amount of a low HLB oil component means an amount effective to solubilize or substantially solubilize a therapeutically effective amount of the poorly water soluble therapeutic agent.
  • substantially solubilize in reference to the solubility of the poorly water soluble therapeutic agent in the low HLB oil component means the poorly water soluble therapeutic agent is soluble in the low HLB oil component oil or has a solubility of more than 1 part per 100 parts of the low HLB oil component by weight at 20°C.
  • the unit dose amount for the low HLB oil component ranges from about 5% to 70% w/w of the microemulsion or emulsion preconcentrate.
  • the amount of omega-3 fatty acid oil in a unit dose of the self-emulsifying microemulsion or emulsion preconcentrate and/or microemulsion or emulsion can be adjusted so that the daily dose of the omega-3 fatty acid oil is from about 1.0 g to about 6.0 g in humans per day, preferably from about 2.0 g to about 5.0 g, most preferably about 2.5 g to about 4.0 g per day.
  • the typical dosage of the omega-3 fatty acid oil ranges from about 14 to 86 mg/kg/day; the typical dosage of a fish oil contains an equivalent amount of omega-3 fatty acid oil.
  • surfactant means a non-ionic or ionic surfactant having an HLB of from about 10 to 20, more preferably 13-19, most preferably 15-18.
  • Suitable surfactants include but are not limited to polyoxyethylene glycolated natural or hydrogenated vegetable oils; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene fatty acid esters; polyoxyethylene alkyl ethers; polyethylene glycol mono- and di- fatty acid esters; transesterification product of natural vegetable oil thglyceride with polyalkylene polyol; and fatty alcohol ethoxylates.
  • Suitable surfactants include Cremophor-RH40, Cremophor-RH60, Cremophor-EL, Tween-20, Tween-40, Tween-60, Tween-65, Tween-80, Tween-85, Labrasol, Nikkol HCO-50, Nikkol HCO-40, Nikkol HCO-60, Brij 30, Gelucire 44/14, Gycerox 767, Imwitor 742, Imwitor 308, Labrafac Lipophile, Labrafac CM 10, Tagat TO, Myrj 52, Myvacet 9-45, and Vitamin E-TPGS.
  • hydrophilic solvent system means a system comprising a solvent or co-solvent (other than the low HLB oil component) with respect to the poorly water soluble therapeutic agent and/or a co- surfactant having an HLB greater than about 20.
  • Example hydrophilic solvent system components include ethanol, alkylene glycols such as propylene glycol, polyethylene glycol, polyoxypropylene block copolymers, Transcutol, Glycofurol, dimethylisosorbide and mixtures thereof.
  • the term "minor amounts" as used in reference to a hydrophilic solvent system means an amount less than about 10% by weight of the components present in the preconcentrate, preferably less than about 5% by weight, most preferably less than the amount of therapeutic agent present in the formulation.
  • the self-emulsifying microemulsion and emulsion preconcentrate and microemulsion and emulsion formulations according to the present invention may optionally include minor amounts of a hydrophilic solvent system to increase the shelf life or stability of the preconcentrates.
  • Other additives, such as antioxidants or preservatives may also be present. Examples include tocopherol, tocopherols excipient, ascorbyl palmitate, butylated hydroxyanisol or other antioxidants and preservatives listed in USP XXII, Parmaceutic Ingredients.
  • the self-emulsifying preconcentrates and the microemulsions and emulsions of the present invention can be adapted for oral administration.
  • Preferred oral dosage forms for the preconcentrates include hard and softgel capsules.
  • Preformed microemulsions and emulsions are preferred oral dosage forms for the microemulsions and emulsions.
  • the formulations according to the present invention can also be administered by other routes of administration, including topical administration or parenteral administration such as i.v. or i.p. administration.
  • the present invention provides for stable, self-emulsifying microemulsion or emulsion preconcentrates comprising a poorly water soluble drug formed from a two-component self-emulsifying system containing an oil component having an HLB ⁇ 4 and a surfactant system containing one or more surfactants, each surfactant having an HLB from about 10 to 20.
  • This two-component system eliminates or drastically reduces the need for substantial amounts of a hydrophilic solvent system, allowing for formulation of preconcentrates that are substantially free of a hydrophilic solvent system or contain only minor amounts of a hydrophilic solvent system.
  • a highly lipophilic oil component and a surfactant system containing surfactants having an HLB from about 10 to 20, preferably 13-19, more preferably 15-18 (in the absence of oils or surfactants having an HLB from about 5 to 10) provides stable preconcentrate systems.
  • These particular components allow formulation of preconcentrates that are substantially free of a hydrophilic solvent system or contain only minor amounts of a hydrophilic solvent system. It is believed that the solubilizing properties of the low HLB oil component in combination with surfactants having and HLB from about 10 to 20 allow for formulation of preconcentrates that are substantially free of hydrophilic solvent system components such as surfactant or co-surfactants having an HLB > 20 or solvents.
  • Enhanced bioavailability for the therapeutic agent from the preconcentrates of the present invention may be due to the absence of these hydrophilic solvent system components that could partition into the aqueous phase upon formation of the microemulsion or emulsion, causing precipitation of the therapeutic agent.
  • a solution containing the poorly water soluble therapeutic agent and the oil component were prepared in appropriate proportions by adding the therapeutic agent in small increments and stirring.
  • the surfactant system was prepared by mixing separately the chosen surfactants in their determined ratios.
  • the oil component/therapeutic agent solution was then combined with the surfactant system solution to form the preconcentrate, such as stirring for approximately 5 minutes with or without heating to 30-40°C until homogeneous.
  • formulations according to the present invention were prepared by simply combining the given amounts of the therapeutic agent, the given amounts of the oil component and the given amounts of the surfactant system with stirring until a homogeneous solution was formed.
  • the therapeutic agent can be added to a mixture of the oil component and the surfactant system and stirred until a homogeneous solution was formed or the surfactant mixture can be prepared, the oil components added to it followed by addition of the drug.
  • the preconcentrate was diluted, such as a 1 :1 , 1 :10, 1 :20, 1 :50 and 1 :100 v/v dilution, with an aqueous solution such as water or simulated gastric fluid to simulate conditions in the stomach.
  • C1 denotes a transparent solution - particle sizing has shown that C1 systems have an average microemulsion droplet sized under 30nm;
  • C2 denotes a translucent solution - droplet size is approximately 50-70nm;
  • C3 denotes a slightly opaque solution - droplet size is in the region of 100nm; and
  • C4 denotes a milky white solution - droplet size is much greater than 100nm.
  • the self-emulsifying microemulsion systems correspond to the C1 to C2 solutions and the self- emulsifying emulsion systems correspond to the C3 to C4 solutions.
  • a ternary phase diagram that maps the different clarity regions for a particular oil component surfactant system can be made to visualize the appropriate ratios needed to form a microemulsion preconcentrate or an emulsion preconcentrate formulation.
  • Oral dosage forms containing the preconcentrates can be prepared.
  • the therapeutic agent-containing preconcentrate can be transferred to a machine for preparing soft capsules and then encapsulated according to conventional methods for producing soft capsules.
  • Samples were prepared according to Example 1 for the oil component, Labrafil M1944CS, and a surfactant system comprising Labrasol and Tween 80 with varying percentages for all three of these components.
  • This system resulted in a C1 microemulsion region that contains the oil component up to approximately 20%.
  • Table 1 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water while Table 2 charts 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, and 100 mg of the therapeutic agent cyclosporin A (CyA) per ml of solution were added.
  • CyA cyclosporin A
  • Samples were prepared according to Example 1 for the oil component, Labrafil M1944CS, and a surfactant system comprising Labrasol and Cremophor RH40 with varying percentages for all three of these components.
  • This system resulted in a C1 or C1/C2 microemulsion region that contains the oil component up to approximately 52%, resulting in an extensive microemulsion region for these preconcentrates as shown in the ternary phase diagram in Fig. 1.
  • This system offers the advantage of good clarity systems at high oil content and thus should offer good solubilization of lipophilic drugs.
  • Table 3 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water while Table 4 charts 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, 100, 150 and 200 mg of the therapeutic agent CyA per ml of solution were added.
  • C1 or C2 systems were obtained with up to 52% oil at 100 mg/ml CyA loading as shown in the ternary phase diagram of Fig. 2.
  • Samples were prepared according to Example 1 for the oil component, Labrafil M1944CS, and a surfactant system comprising Tween 80 and Cremophor RH40 with varying percentages for all three of these components.
  • This system resulted in a C1 or C1/C2 microemulsion region that contains the oil component up to approximately 55%, resulting in an extensive microemulsion region for these preconcentrates.
  • This system offers the advantage of good clarity systems at high oil content and thus should offer good solubilization of lipophilic drugs.
  • Table 5 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water while Table 6 charts 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, and 100 mg of the therapeutic agent CyA per ml of solution were added.
  • C1 or C2 systems were obtained with up to 27% oil at 100 mg/ml CyA loading.
  • Samples were prepared according to Example 1 for the oil component, Labrafil M1944CS, and a surfactant system comprising Cremophor RH40, Tween 80 and Labrasol.
  • the ratio of Cremophor RH40 to Tween 80 was held constant at either 2:1 or 4:1 while the amounts of Labrasol, Labrafil and Cremophor RH40/Tween 80 were varied.
  • the placebo system resulted in a C1 or C1/C2 microemulsion region that contained the oil component up to approximately 45%, resulting in an extensive microemulsion region for these preconcentrates.
  • C1/C2 systems were obtained for points examined between 20% and 50% oil content.
  • the placebo system results in a C1 or C1/C2 microemulsion region for up to about 45% oil content. Similar clarity systems were obtained with 50mg/ml and 100 mg/ml CyA loading. This system offers the advantage of good clarity systems at high oil content and thus should offer good solubilization of lipophilic drugs.
  • the following formulation was prepared and encapsulated in softgel capsules.
  • Example 6 Labrafil M1944CS / Tween 80 / Cremophor RH40 / Labrasol / Therapeutic Agents Indomethacin and Nifedipine
  • Samples were prepared according to Example 1 for the oil component, Labrafil M1944CS, and a surfactant system comprising Cremophor RH40, Tween 80 and Labrasol.
  • the ratio of Cremophor RH40 to Tween 80 was held constant at either 1 :1 , 1 :2, 2:1 or 4:1 while the amounts of Labrasol, Labrafil and Cremophor RH40/Tween 80 were varied.
  • Table 7 and 8 describe the clarity values upon 1 to 20, 1 to 50 and 1 to 100 dilution in deionized water at 37°C for the placabo systems.
  • nifedipine in microemulsion preconcentrates was examined at 25, 50 and 100 mg/g.
  • Cremophor RH40 to Tween 80 ratios of 1 :2, 1:1, 2:1 and 4:1 25 mg nifedipine was fully soluble in all preconcentrates; 50 mg was solubilized in compositions with oil content up to 35%.
  • Dilution of the nifedipine-loaded preconcentrate at all compositions for the 25 mg/g and at an oil content of up to 35% for the 50 mg/g nifedipine formulations produced an extensive microemulsion region with C1 or C1/C2 clarity being observed. 1 to 50 and 1 to 100 dilutions were also investigated.
  • Table 10 shows the clarity values for 25 mg/g nifedipine in the 1:1 , 1:2, 2:1 and 4:1 Cremophor RH40 to Tween systems described above. Sizing of various samples in a Malvern Mastersizer S using a flow-through cell show that the visually determined C3 values correspond to a mean particle size of less than about 500 nm and C2 values correspond to a mean particle size of less than about 300 nm.
  • cyclosporin A was determined in polyunsaturated omega-3 free fatty acid oil EPAX6000FA , in omega-3 fatty acid glyceride oils EPAX5000TG, EPAX4510TG, EPAX2050TG, and K85TG, in omega-3 fatty acid ethyl ester K85EE and in a mixture of free fatty acid and ethyl ester EPAX6000FA/K85EE (Pronova Biocare, Sandefjord, Norway).
  • the K85TG is a mixed glyceride form obtained by transesterification of K85EE with glycerol giving the resulting blend: K85 monoglyceride: 5-15%; K85 diglyceride: 20-30%; K85 triglyceride: 50-70% and K85EE remnants: ⁇ 5%. All of these oils have an HLB ⁇ 4. Further details regarding these omega-3 fatty acid oils and the CyA solubilities are given in Table 11.
  • Samples were prepared according to Example 1 for the omega-3 fatty acid oil K85EE and a surfactant system comprising Labrasol and Cremophor RH40 with varying percentages for all three of these components.
  • Table 12 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water while Table 13 charts 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, 100 and 150 mg of CyA per ml of solution were added. From an analysis of the placebo system, it appears that the greatest amount of oil possible in a microemulsion preconcentrate formulation formulated according to this system is around 40-45% K85EE.
  • Samples were prepared according to Example 1 for the omega-3 fatty acid oil K85EE and a surfactant system comprising Labrasol and Tween 80 with varying percentages for all three of these components.
  • Table 14 charts the clarity values upon 1 to 20 dilution with water for this system (placebo) while Table 15 charts the 1 to 20 dilution clarity values for corresponding systems in which 25 and 50 mg of CyA per ml of solution were added.
  • Samples were prepared according to Example 1 for the omega-3 fatty acid oil K85EE and a surfactant system comprising Labrasol, Tween 80 and Cremophor RH40 (holding the ratio of Cremophor RH40 to Tween 80 at 2:1) with
  • Table 16 charts the 1 to 20 dilution clarity values for this system (placebo) as well as the corresponding system with 5% Ethanol included also.
  • Table 17 charts 1 to 20 dilution clarity values for corresponding systems in which 100 mg of CyA per ml of solution has been added.
  • Tables 16 and 17 show that inclusion of 5% ethanol compared to the same system without ethanol provides similar microemulsion region sizes for both placebo systems (20% to 50% oil) and the corresponding 100 mg/ml CyA systems.
  • Samples were prepared according to Example 1 for the omega-3 fatty acid oil EPAX5000TG and a surfactant system comprising Labrasol and Cremophor RH40 with varying percentages for all three of these components.
  • Table 18 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water as well as 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, 100 and 150 mg of CyA per ml of solution were added.
  • Samples were prepared according to Example 1 for the omega-3 fatty acid oil K85TG and a surfactant system comprising Labrasol, Cremophor RH40 and Tween 80 (with Cremophor RH40 and Tween 80 held at a 2:1 ratio) with varying percentages for the oil, Labrasol and the Cremophor RH40 and Tween 80 mixture.
  • Table 20 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water.
  • a pseudo-ternary phase diagram showing the microemulsion region (C1 , C1/C2, and C2 clarity values) for this placebo system upon 1 to 20 dilution is shown in Figure 3.
  • Table 21 charts the 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, 100 and 150 mg of CyA per ml of solution were added.
  • the pseudo-ternary phase diagram given in Figure 4 shows the microemulsion region for the system upon 1 to 20 dilution having 100 mg/ml CyA per ml of solution.
  • Samples were prepared according to Example 1 for the omega-3 fatty acid oil K85TG and a surfactant system comprising Labrasol and Cremophor RH40 with varying percentages for all three of these components.
  • Table 22 charts the clarity values for this system (placebo) upon 1 to 20 dilution with water as well as 1 to 20 dilution clarity values for the corresponding systems in which 25, 50, 100 and 150 mg of CyA per ml of solution were added. From an analysis of the placebo system, it appears that the greatest amount of oil possible in a microemulsion preconcentrate formulation formulated according to this system is around 27% K85TG.
  • microemulsion region on a ternary phase diagram obtained by plotting the data for the K85EE/Cremophor/Labrasol system provided in this example is similar to that for the corresponding EPAX5000TG system (Example 11) and the EPAX6000FA system (Example 12) over a range of 0 to 150 mg/ml CyA.
  • the corresponding K85EE system (Example 8) appears to form a larger microemulsion region than the K85TG system.
  • Samples were prepared according to Example 1 for the systems containing a mixture of K85EE and EPAX6000FA and a surfactant system comprising Labrasol, Tween 80 and Cremophor RH40 with varying percentages as described in Table 23.
  • Table 23 charts the clarity values for these systems (placebo) upon 1 to 20 dilution with water as well as 1 to 20 dilution clarity values for the corresponding systems in which 50 or 100 mg of CyA per ml of solution were added. There was a slight improvement in the clarity of the resulting microemulsions upon the addition of CyA.
  • the following formulations according to the present invention were prepared as follows.
  • the given amounts of cyclosporin, the given amounts of the oil containing omega-3 fatty acid oil, and the given amounts of the surfactant system were stirred until a homogeneous solution was formed.
  • the resulting cyclospo n-containing composition was transferred to a machine for preparing soft capsules and then encapsulated according to conventional methods for producing soft capsules.
  • Preconcentrate formulations suitable for formulation with a therapeutically effective amount of a poorly water soluble theraputic agent according to this invention and containing ethyl oleate were prepared as detailed in Table 24 (w/w %).
  • the respective amounts of Cremophor RH40 and Tween 80 (2:1) were weighed out initially and allowed to mix at approximately 37°C until homogenous. Following this, Labrasol was added as required and all three surfactants were allowed combine until they had formed a clear homogenous mix. The appropriate oil component was added to the mixture of surfactants and allowed to mix. Finally, ethanol was included if present.
  • Microemulsions were formed by diluting 1 :20 with deionised water and microemulsion formation was assessed. The average particle size was measured by photon correlation spectroscopy (C3 and C4 formulations diluted up to 1:400 as necessary) as shown in Table 24.
  • Labrasol composition was found to influence droplet size, which increased to 74.5nm and 113.3nm for a Labrasol concentration of 5% and 10% respectively.
  • a hazy preconcentrate with a C4 microemulsion of droplet size 135.8nm was produced.
  • preconcentrate formulations suitable for formulation with a therapeutically effective amount of a poorly water soluble theraputic agent according to this invention and containing oleic acid were prepared and assessed as detailed in Table 25 (w/w %).
  • the preconcentrates produced were clear, one-phased systems on formulation, and showed no sign of phase separation or streaking after being left to stand for 24hrs.
  • Dilution (1 in 20) of the 15% and 30% oleic acid preconcentrates gave a clarity of C4 and an average particle size of 194.0nm and 211.3nm respectively.
  • Concentrations of 37% and 50% oleic acid were used to make up preconcentrates, in conjunction with 5% Labrasol, 5% ethanol and Cremopho ⁇ Tween (2:1) as required. Both formulations gave one phase, clear, pale yellow preconcentrates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP99921098A 1998-05-07 1999-05-07 Mikroemulsion frei von lösungsmittel und co-lösungsmittel und emulsionvorkonzentrat als wirkstoff freisetzungssytemen Withdrawn EP1075252A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8451898P 1998-05-07 1998-05-07
US84518P 1998-05-07
PCT/IE1999/000031 WO1999056727A2 (en) 1998-05-07 1999-05-07 Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems

Publications (1)

Publication Number Publication Date
EP1075252A2 true EP1075252A2 (de) 2001-02-14

Family

ID=22185451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921098A Withdrawn EP1075252A2 (de) 1998-05-07 1999-05-07 Mikroemulsion frei von lösungsmittel und co-lösungsmittel und emulsionvorkonzentrat als wirkstoff freisetzungssytemen

Country Status (5)

Country Link
EP (1) EP1075252A2 (de)
JP (1) JP2002513750A (de)
AU (1) AU3843999A (de)
CA (1) CA2331640A1 (de)
WO (1) WO1999056727A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1154759T3 (da) 1998-12-30 2008-12-08 Dexcel Ltd Dispergerbart koncentrat til indgift af cyclosporin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU7638200A (en) * 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions
EP1762557B1 (de) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-ausgelöste Lipidmediatoren
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs
US6596306B1 (en) * 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
DE60137069D1 (de) * 2000-10-11 2009-01-29 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
MXPA03007141A (es) * 2001-02-11 2003-11-18 Aquanova Ger Solubilisate Tech Procedimiento para la preparacion de un concentrado de ingredientes activos, y un concentrado de ingredientes activos.
AU2002231970B2 (en) * 2001-02-14 2007-08-16 CNX Therapeutics Limited Mucoadhesive pharmaceutical formulations
DE50101395D1 (de) * 2001-04-12 2004-03-04 Vesifact Ag Baar Pharmazeutische Formulierungen enthaltend entzündungshemmende Wirkstoffe und deren Verwendung
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
WO2003053423A2 (en) 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2003258194B2 (en) 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
JP4886297B2 (ja) * 2002-11-01 2012-02-29 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド ジオデート送達媒体
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US7879345B2 (en) 2003-04-11 2011-02-01 L'oreal Composition containing an amphiphilic polymer, uses thereof
FR2853527B1 (fr) * 2003-04-11 2006-06-23 Oreal Composition sous forme d'une emulsion huile-dans-eau contenant un polymere amphiphile, et ses utilisations notamment cosmetiques
CA2558393A1 (en) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
CA2562388A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
US20050232974A1 (en) * 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
CA2573316A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
CN100361656C (zh) 2004-08-27 2008-01-16 石药集团中奇制药技术（石家庄）有限公司 丁苯酞自乳化释药体系及其制备方法和应用
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US20140287004A1 (en) * 2005-11-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs
US20070149617A1 (en) * 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
CN101547687A (zh) * 2005-11-17 2009-09-30 生物药效率有限公司 生物相容的潜在乳化剂
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
CA2664427C (en) * 2006-10-04 2012-06-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
KR101493546B1 (ko) * 2007-08-21 2015-02-16 바실리어 파마슈티카 아게 항균 조성물
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
FR2925855B1 (fr) 2007-12-26 2010-11-05 Virbac Sa Composition liquide autoemulsionnable de florfenicol destinee a etre incorporee a l'eau de boisson des animaux d'elevage.
US9532963B2 (en) 2009-03-09 2017-01-03 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
JP2011006380A (ja) * 2009-05-22 2011-01-13 Mochida Pharmaceut Co Ltd ω３脂肪酸の乳化組成物
CA3059911C (en) 2009-05-22 2022-01-11 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
ES2661812T3 (es) 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
KR101904388B1 (ko) * 2009-10-23 2018-10-05 프로노바 바이오파마 너지 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
DK2366408T3 (da) 2010-03-01 2012-10-22 Salvat Lab Sa Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
KR20130103521A (ko) * 2010-09-08 2013-09-23 프로노바 바이오파마 너지 에이에스 지방산 오일 혼합물, 유리 지방산, 및 스타틴을 포함하는 조성물
KR20130139896A (ko) * 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
SG11201505076UA (en) 2012-12-31 2015-07-30 Jrx Biotechnology Inc Liquid topical pharmaceutical nano-emulsion formulations
CN105263321B (zh) 2013-03-28 2018-07-27 哥伦比亚大学纽约管理委员会 用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
US11400048B2 (en) 2014-06-25 2022-08-02 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
WO2015198350A1 (en) * 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
US12303504B2 (en) * 2018-09-13 2025-05-20 Oncosol Limited Non-aqueous chemotherapeutic suspensions for oral dosage
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20200215027A1 (en) * 2018-12-28 2020-07-09 Robert K. Prud'homme Dihydromyricetin nanoemulsion formulations and methods for forming them
US11465107B2 (en) * 2019-01-31 2022-10-11 Hong Ngoc Thi Dang Process for producing a nano omega-3 microemulsion system
JP6880352B1 (ja) 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
CN1077800C (zh) * 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
FR2710535B1 (fr) * 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
IL107471A (en) * 1993-11-02 1997-09-30 Yissum Res Dev Co Pharmaceutical preparation comprising a self- emulsifying formulation and process for its production
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
EP0760237A1 (de) * 1995-08-30 1997-03-05 Cipla Limited Öl-in-Wasser-Mikroemulsionen
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
FR2753376B1 (fr) * 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
KR100587551B1 (ko) * 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
AU1809499A (en) * 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9956727A3 *

Also Published As

Publication number Publication date
WO1999056727A3 (en) 2000-03-02
AU3843999A (en) 1999-11-23
WO1999056727A2 (en) 1999-11-11
CA2331640A1 (en) 1999-11-11
JP2002513750A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
AU743098B2 (en) Pharmaceutical compositions containing an omega-3 fatty acid oil
WO1999056727A2 (en) Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
EP1035862B1 (de) Cyclosporin-enthaltende mikroemulsion-vorkonzentratzusammensetzung
JP3391961B2 (ja) サイクロスポリン含有軟質カプセル剤組成物
SK52197A3 (en) Pharmaceutical compositions
JP2002505271A (ja) サイクロスポリン類またはマクロライド含有エマルジョン前濃縮物
CA2283780A1 (en) Lipophilic binary systems for the administration of lipophilic compounds
US6028067A (en) Cyclosporin-containing microemulsion preconcentrate composition
EP1413297A1 (de) Cyclosporin enthaltende Weichkapselpräparate
KR101068256B1 (ko) 시클로스포린을 포함하는 경구용 약학적 조성물
KR100300251B1 (ko) 사이클로스포린함유약학적조성물
AU6729398A (en) Pharmaceutical compositions
KR20070096142A (ko) 흡수율 증진을 위한 타크로리무스 나노에멀젼 및 그의제조 방법
MXPA00005507A (es) Composicion preconcentrada en forma de microemulsion que contiene ciclosporina

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001027

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020718

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021129